# RAVES (NCT00860652)

> Radiotherapy - Adjuvant Versus Early Salvage

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00860652
- Phase: NA
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Trans Tasman Radiation Oncology Group
- Conditions: Prostate Cancer
- Interventions: Adjuvant Radiotherapy; Early Salvage Radiotherapy
- Enrollment: 333
- Primary outcome: Biochemical failure: PSA ≥ 0.4 ng/ml and rising following RT

## Commentary we found

- X threads: 22
- Podcasts: 5
- YouTube: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=raves-nct00860652

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00860652", "email": "<work email>"}; the inbox owner confirms by the emailed link.